News >

Emerging Agents, Treatment Selection Criteria Key to Improving Outcomes in Myelofibrosis

Jessica Hergert
Published: Monday, Jan 20, 2020

Neil Dunavin, MD, MS, a clinical hematologist and assistant professor of medicine at the University of California, San Francisco

Neil Dunavin, MD, MS

Choosing the optimal treatment for patients with myelofibrosis remains a challenge in clinical practice, explained Neil Dunavin, MD, MS. However, factors can be taken into consideration that can help with making that decision, he said.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication